Active Pharmaceutical ~HETERO Ingredients
8
_J Active Pharmaceutical Ingredients 2019 L ~HETERO
Transcript of Active Pharmaceutical ~HETERO Ingredients
_J
Active Pharmaceutical
Ingredients 2019
L
~HETERO
_J
7
Active Pharmaceutical Ingredients
-1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
ANTI HYPERTENSIVES
Alfuzosin HCI BP/EP/ USP
Aliskiren Hemifumarate
Amlodipine Besylate BP/EP/ USP
Azelnidipine
Azilsartan Kamedoxomil
S-Amlodipine Besylate
Benazepril HCI BP/EP/ USP
Bosentan Hydrate
Candesartan Cilexetil BP/EP/ USP
Carvedilol BP/EP/ USP
Cilazapril BP/EP
Cilnidipine
Doxazosin Mesylate BP/EP/ USP
Droxidopa
Enalapril Maleate BP/EP/ USP
Eplerenone BP/EP
Eprosartan Mesylate
Fosinopril Sodium BP/EP/ USP
Hydralazine HCI BP/EP/ USP
lrbesartan BP/EP/ USP
lsradipine BP/EP/ USP
lvabradine HCI
Lercanidipine HCI
Lisinopril BP/EP/ USP
Losartan Potassium BP/EP/ USP
Macitentan
Moxonidine BP/EP
Naftopidil
Nebivolol HCI
Nisoldipine
Olmesartan Medoxomil BP/EP/ USP
Perindopril Erbumine BP/EP/ USP
Quinapril HCI BP/EP/ USP
Ramipril BP/EP/USP
Ranolazine
36. Selexipag
37. Telmisartan BP/EP/ USP
38. Terazosin HCI BP/EP/ USP
39. Trandolapril BP/EP/ USP
40. Valsartan BP/EP/ USP - ANTIHYPERLIPOPROTEINEMICS
41. Atorvastatin Calcium BP/EP/ USP
42. Ciprofibrate BP/EP
43. Colesevelam HCI
44. Ezetimibe
45. Fluvastatin Sodium BP/EP/ USP
46. Pitavastatin Calcium
47. Rosuvastatin Calcium BP/EP
48. Simvastatin BP/EP/ USP - ANTI ULCERATIVES
49. Alvimopan
50. Acotiamide HCI Hydrate
51. Balsalazide Disodium USP
52. Cinitapride Hydrogen Tartrate
53. Dexlansoprazole
54. Esomeprazole Magnesium BP/EP/ USP
55. Esomeprazole Sodium
56. 1 laprazole
57. lrsogladine Maleate
58. ltopride HCI
59. Lafutidine
60. Lansoprazole E.C.Pellets
61. Lansoprazole BP/EP/ USP
62. Mosapride Citrate
63. Omeprazole E.C.Pellets
64. Omeprazole BP/EP/USP
65. Omeprazole Magnesium BP/EP/ USP
66. Omeprazole Sodium BP/EP
67. Pantoprazole Sodium BP/EP/ USP
68. Rabeprazole Sodium EP/ USP
69. Rebamipide
D1scla1mer The products covered under valid and enforceable patents In India or elsewhere, will be supplied solely for the Research & Development purposes, and subm1ss1on of 1nformat1on required by Regulatory Agencies In India or elsewhere, according to the sect1onl 07A of the Indian Patent Act, 1970 Buyers will be solely responsible for any l1ab1l1ty associated with the infringement of patents, In their respective markets
L
_J
7
70. Roxatidine Acetate HCI
71. Sofalcone - ANTIDEPRESSANTS/ ANTI PSYCHOTICS
72. Agomelatine
73. Aripiprazole EP/BP/ USP
74. Aripiprazole Lauroxil
75. Asenapine Maleate
76. Atomoxetine HCI BP/EP/ USP
77. Brexpiprazole
78. Cariprazine HCI
79. Citalopram HBr BP/EP/ USP
80. Desvenlafaxine Succinate Pellets
81. Duloxetine HCI BP/EP/ USP
82. Escitalopram Oxalate USP/ EP
83. Eszopiclone USP
84. lloperidone
85. Levosulpiride
86. Lurasidone HCI
87. Meprobamate BP/EP/ USP
88. Milnacipran HCI
89. Olanzapine Form I BP/EP/ USP
90. Paliperidone USP
91. Quetiapine Fumarate BP/EP/ USP
92. Risperidone BP/EP/ USP
93. Sertraline HCI (Form I & 11) BP/EP/ USP
94. Venlafaxine HCI BP/EP/ USP
95. Zaleplon USP
96. Ziprasidone HCI BP/EP/ USP
97. Zopiclone BP/EP
98. Zotepine - ANTI-THROMBOTICS
99. Cangrelor Tetrasodium
100. Cilostazol USP
101. Clopidogrel Hydrogen bisulphate BP/EP/ USP
102. Edoxaban Tosylate
103. Ozagrel HCI/Na
104.
105.
106.
107. -108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124. -125.
126.
127.
128.
129.
130.
131.
132.
134.
135.
136.
137.
138.
Picotamide BP/ EP
Prasugrel HCI
Sarpogrelate HCI
Ticagrelor
ANTI DIABETICS
Anagliptin
Canagliflozin
Dapag I iflozi n
Epalrestat
Fidarestat
Glimepiride BP/EP/USP
Miglitol
Nateglinide BP/EP/ USP
Omarigliptin
~HETERO
Pioglitazone HCI BP/EP/ USP
Repaglinide BP/EP/ USP
Rosiglitazone Maleate USP
Saxagliptin HCI
Sitagliptin Phosphate EP /HCI
Teneligliptin HBr.H2O
Trelagliptin Succinate
Voglibose
ANTI FUNGALS
Butenafine HCI
Crisaborole
Dapaconazole Tosylate
Efinaconazole
Fluconazole BP/EP/ USP
ltraconazole BP/EP/ USP
ltraconazole Pellets
Oxiconazole Nitrate
Posaconazole
Sertaconazole Nitrate BP/EP
Sulconazole Nitrate USP
Tavaborole
Terbinafine HCI BP/EP/ USP
D1scla1mer The products covered under valid and enforceable patents In India or elsewhere, will be supplied solely for the Research & Development purposes, and subm1ss1on of 1nformat1on required by Regulatory Agencies In India or elsewhere, according to the sect1onl 07A of the Indian Patent Act, 1970 Buyers will be solely responsible for any llab1l1ty associated with the infringement of patents, In their respective markets.
L
_J
7
Active Pharmaceutical Ingredients
139. Tioconazole BP/EP/USP
140. Voriconazole BP/EP/ USP - ANTIHISTAMINICS, ANTIASTHMATICS
141. Carbinoxamine Maleate USP
142. Cetirizine Di HCI BP/EP/ USP
143. Desloratadine BP/EP/ USP
144. Fexofenadine HCI BP/EP/ USP
145. Fluticasone Propionate BP/EP/ USP
146. Hydroxyzine HCI BP /EP/USP
147. Levocetirizine Di HCI USP
148. Loratadine BP/EP/ USP
149. Meclizine HCI BP/EP/ USP
150. Montelukast Sodium BP/EP/ USP
151. Olopatadine HCI USP
152. Pirfenidone BP/EP
153. Roflumilast
154. Rupatadine Fumarate EP - ANTI-INFLAMMATORY
155. Amtolmetin Guacil
156. Celecoxib BP/EP/ USP
157. Deflazacort
158. Etoricoxib
159. Ketorolac Tromethamine BP/EP/ USP
160. Leflunomide BP/EP/ USP
161. Lornoxicam
162. Loxoprofen Sodium
163. Olsalazine Sodium BP/EP
164. Oxaprozin USP
165. Parecoxib Sodium
166. Polmacoxib
167. Zaltoprofen - ANTINEOPLASTICS
168. Abiraterone Acetate USP
169. Alectinib hydrochloride
170. Anastrozole BP/EP/ USP
171. Aprepitant BP/EP/ USP
172. Fosaprepitant Dimeglumine
173. Bendamustine HCI
174. Bexarotene
175. Bicalutamide BP/EP/ USP
176. Bortezomib
177. Cabazitaxel
178. Cabozantinib
179. Carfilzomib
180. Carmustine BP/EP/USP
181. Capecitabine BP/EP/ USP
182. Ceritinib
183. Cladribine BP/EP/USP
184. Crizotinib
185. Daunorubicin HCI BP/EP/USP
186. Docetaxel BP/EP/ USP
187. Doxorubicin HCI BP/EP/ USP
188. Enzalutamide EP/ USP
189. Erlotinib HCI
190. Exemestane BP/EP/ USP
191. Gefitinib BP/EP
192. Gemcitabine HCI BP/EP/ USP
193. lbrutinib
194. ldelalisib
195. lmatinib Mesylate BP/EP
196. lrinotecan HCI USP/ EP
197. lxazomib Citrate
198. Lenalidomide
199. Lenvatinib Mesylate
200. Letrozole BP/EP/ USP
201. Melphalan HCI EP/ USP
202. Neratinib Maleate
203. Niraparib
204. Olaparib
205. Osimertinib Mesylate
206. Paclitaxel BP/EP/ USP
207. Palbociclib
D1scla1mer The products covered under valid and enforceable patents In India or elsewhere, will be supplied solely for the Research & Development purposes, and subm1ss1on of 1nformat1on required by Regulatory Agencies In India or elsewhere, according to the sect1onl 07A of the Indian Patent Act, 1970 Buyers will be solely responsible for any l1ab1l1ty associated with the infringement of patents, In their respective markets
L
_J
7
208.
209.
210.
211.
212.
213.
214.
215.
216.
217.
218. -219.
220.
221.
222.
223.
224.
225.
226.
227.
228.
229.
230.
231. -232.
233.
234.
235.
236.
237. -238.
239.
240.
Pemetrexed Disodium BP/EP/ USP
Pomalidomide
Ribociclib
Ruxolitinib
Sunitinib Malate
Thalidomide USP
Tipiracil HCI
Toremifene Citrate
Trametinib Dimethyl Sulfoxide
Venetoclax
Vorinostat
ANTIBACTERIALS
Balofloxacin
Cilastatin BP/EP/ USP
Garenoxacin Mesylate
Gemifloxacin Mesylate
Levofloxacin USP
Linezolid USP
Lomefloxacin HCI
Moxifloxacin HCI BP/EP/ USP
Nadifloxacin
Pazufloxacin Mesylate
Prulifloxacin
Tedizolid Phosphate
Vigabatrin BP/EP/ USP
CARBAPENEMS
Biapenem
Doripenem
Ertapenem Na
Faropenem Na
lmipenem BP/EP/USP
Meropenem Sterile BP/EP/ USP
CEPHALOSPORINS
Cefdinir USP
Cefditoren Pivoxil
Cefepime HCI Sterile BP/EP/ USP
241.
242.
243.
244.
245.
246.
247.
248. -249.
250.
251.
252.
253.
254.
255.
256.
257. -258.
259.
260.
261.
262.
263. --264.
265.
266.
267.
268.
~HETERO
Cefetamet Pivoxil
Cefixime BP/EP/USP
Cefoxitin Sodium BP/EP/USP
Cefpodoxime Proxetil BP/EP/ USP
Cefprozil BP/EP/ USP
Ceftazidime Sterile BP/EP/USP
Ceftriaxone Sodium Sterile BP/EP/USP
Ceftibuten
ANTIVIRALS
Acyclovir BP/EP/ USP
Adefovir Dipivoxil
Arbidol HCI
Famciclovir USP
Foscarnet Sodium BP/EP/ USP
Ganciclovir BP/EP/ USP
Oseltamivir Phosphate BP/EP/ USP
Valacyclovir HCI BP/EP/ USP
Valganciclovir HCI USP
ANTIVI RAL/H EPATITIS-C
Elbasvir
Grazoprevir
Ledipasvir
Simeprevir
Sofosbuvir
Velpatasvir
ANTI RETROVI RALS
NRTl's
Abacavir Sulphate BP/EP/ USP
Didanosine BP/ EP/ USP
Emtricitabine USP
Lamivudine BP/EP/USP
Stavudine BP/EP/ USP
269. Tenofovir Disoproxil Fumarate/ Alafenamide
270. Zidovudine BP/EP/USP - NNRTl's
271. Doravirine
D1scla1mer The products covered under valid and enforceable patents In India or elsewhere, will be supplied solely for the Research & Development purposes, and subm1ss1on of 1nformat1on required by Regulatory Agencies In India or elsewhere, according to the sect1onl 07A of the Indian Patent Act, 1970 Buyers will be solely responsible for any llab1l1ty associated with the infringement of patents, In their respective markets.
L
_J
7
Active Pharmaceutical Ingredients
272. Efavirenz USP
273. Etravirine
27 4. Nevi rapine BP/EP/ USP
275. Rilpivirine HCI - PROTEASE INHIBITORS
276. Atazanavir Sulphate
277. Darunavir Amorphous/ Ethanolate
278. Fosamprenavir Ca
279. lndinavir Sulphate BP/EP/ USP
280. Lopinavir BP/EP/ USP
281. Nelfinavir Mesylate
282. Ritonavir BP/EP/ USP
283. Saquinavir Mesylate BP/EP/ USP - INTEGRASE INHIBITORS
284. Dolutegravir Sodium
285. Raltegravir Potassium - ENTRY INHIBITORS
286. Maraviroc - ANTIMIGRAINES
287. Eletriptan HBr
288. Frovatriptan Succinate
289. Naratriptan HCI USP
290. Rizatriptan Benzoate BP/EP/ USP
291. Zolmitriptan USP - ANTICONVULSANTS/ ANTI EPILEPTICS
292. Felbamate USP
293. Gabapentin BP/EP/ USP
294. Lacosamide EP
295. Lamotrigine BP/EP/ USP
296. Levetiracetam BP/EP/ USP
297. Eslicarbazepine Acetate
298. Oxcarbazepine BP/EP/ USP
299. Pregabalin BP/EP/ USP
300. Retigabine
301. Rufinamide USP
302. Tiagabine HCI USP
303. Topiramate USP
304. Zonisamide USP - ANTIOSTEOPOROTIC
305. Alendronate Sodium BP/EP/ USP
306. lbandronate Sodium
307. Minodronic Acid
308. Pamidronate Disodium BP/EP/ USP
309. Raloxifene HCI BP/EP/ USP
31 0. Risedronate Sodium BP/EP/ USP
311. Zoledronic Acid - FOR OVERACTIVE BLADDER
312. Darifenacin HBr
313. Mirabegron
314. Solifenacin Succinate BP/EP - URINARY INCONTINENCE
315. Fesoterodine Fu ma rate EP/ USP
316. Tolterodine Tartrate BP/EP/ USP - MULTIPLE SCLEROSIS
317. Teriflunomide - DIURETICS
318. Torsemide BP/EP/ USP - ANTIMALARIALS
319. Atovaquone BP/EP/ USP
320. Proguanil HCI BP/EP/ USP - ANTI GLAUCOMA
321. Brimonidine Tartrate BP/EP
322. Brinzolamide USP
323. Dorzolamide HCI BP/EP/ USP - ANTISPASMODIC
324. Trospium Chloride BP/EP/ USP - ANTI HYPERPARATHYROI D
325. Cinacalcet HCI
326. Doxercalciferol
327. Paricalcitol USP
D1scla1mer The products covered under valid and enforceable patents In India or elsewhere, will be supplied solely for the Research & Development purposes, and subm1ss1on of 1nformat1on required by Regulatory Agencies In India or elsewhere, according to the sect1onl 07A of the Indian Patent Act, 1970 Buyers will be solely responsible for any l1ab1l1ty associated with the infringement of patents, In their respective markets
L
_J
7
~HETERO
- ERECTILE DYSFUNCTION - FOR SEVERE DYSPAREUNIA
328. Sildenafil Citrate BP/EP/ USP 352. Ospemifene
329 Tadalafil BP/EP/ USP - ANTIPSORIATIC
330. Vardenafil HCI BP/EP 353. Apremilast - ANTI-ALZHEIMER - ANTIARRHYTHMIC
331. Donepezil HCI USP 354. Dronedarone HCI USP
332. Galantamine HBr BP/EP/ USP - COPPER-CHELATING AGENT
333. Rivastigmine Hydrogen Tartrate BP/EP/ USP 355. Trientine Dihydrochloride EP/ USP - ANTI PARKINSONIANS - PRIMARY BILIARY CHOLANGITIS
334. Entacapone BP/EP/ USP 356. Obeticholic Acid
335. Memantine HCI USP - CYSTIC FIBROSIS
336. Pramipexole Di HCI BP/EP/ USP 357. Lumacaftor
337. Rasagiline Mesylate 358. lvacaftor
338. Ropinirole HCI BP/EP/ USP - INSOMNIA - ABORTI FACI ENT 359. Suvorexant
339. Mifepristone - NAUSEA & VOMITING - MUSCLE RELAXANT 360. Rolapitant
340. Cyclobenzaprine HCI USP - RHEUMATOID ARTHRITIS
341. Eperisone HCI 361. Baricitinib
342. Tizanidine HCI BP/EP/ USP - MYOCARDIAL INFARCTION - ANTIDIARRHEALS 362. Vorapaxar Sulfate
343. Eluxadoline
344. Racecadotril BP/EP - TREATMENT OF BPH
345. Dutasteride BP/EP/ USP
346. Finasteride BP/EP/USP
347. Tamsulosin HCI BP/EP/ USP - NEUROPROTECTIVE
348. Riluzole USP - ANOREXIA
349. Phentermine HCI USP - FOR HYPERURICEMIA
350. Febuxostat - IMMUNOMODULATOR
351. Fingolimod HCI USP
D1scla1mer The products covered under valid and enforceable patents In India or elsewhere, will be supplied solely for the Research & Development purposes, and subm1ss1on of 1nformat1on required by Regulatory Agencies In India or elsewhere, according to the sect1onl 07A of the Indian Patent Act, 1970 Buyers will be solely responsible for any llab1l1ty associated with the infringement of patents, In their respective markets.
L
Why Partner Hetero?
• 25+ Years of expertise in pharmaceuticals
• Vertically integrated pharmaceutical company
• World-class R&D supported by cutting-edge technologies
• Global leader in ARV APls and Finished Dosages
• 36 manufacturing facilities approved by global regulatory authorities
• Compliance to cGMP practices ensuring high-quality standards
• Portfolio of 300+ products
• Established presence in 126+ countries
• Trusted Partner of Choice for customers worldwide
For more information on Hetero, please visit
www.heteroworld.com
[1t!HETERO Hetero Corporate 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. Telangana, INDIA Phone: +91 40 23704923 / 24 / 25 Email: [email protected]
Follow us on: 11 ~ ~ a
